Firalis expands its bioanalytical platform & service offer


Firalis proudly announces the integration of a new analytical technology and the expansion of its biomarker service offerings.The new instrument made available is the Singulex "single molecule counting" immunoassay technology called Erenna®.

Erenna® system allows:

  • Quantification of analytes at ultrasensitive levels (at femtogram/mL concentrations).
  • Unparalleled precision and accuracy with lower sample volumes and lower analyte concentrations.
  • A method to rapidly develop your own assays with your proprietary antibodies and calibrators.

The Erenna® system is of particular relevance for the measurement of some markers, especially in the field of cardiovascular medicine and inflammation research.

This new technology complement the existing bioanalytical platform composed of the following:
MSD Sector Imager 6000, Bio-Plex 200, Enspire, Siemens Dimension and ABI Prism 9700.

Assays developed on the new platform will be integrated in the laboratory GLP system (ISO 17025) and assays will be object of extensive validation and third party auditing.

This addition will be an additional added value for customers that are now offered a wide range of possibilities in their biomarker development projects.


Firalis SAS is a privately owned life sciences company, creating novel values via biomarker discovery, development and regulatory qualifications; to establish an internal portfolio of biomarker-based diagnostic methods and to provide customized biomarker solutions. Firalis is active in the field of drug safety, cardiovascular, inflammatory and autoimmune diseases. The company has been awarded with several national and international prizes for its innovative approaches.

Firalis SAS, 35 Rue du Fort, 68330 Huningue - FRANCE

+33 389 911 320-8 /  / /

Comments are closed.